<?xml version="1.0" encoding="UTF-8"?>
<ack>
 <title>Acknowledgments</title>
 <p>We thank Dr Jean Marie Quésada, biostatistician at the Grenoble Clinical Investigation Center (INSERM CIC 1406), for his help in data analysis, Valérie Rolland-Neyret and Roseline Delepine, data coordinators of the trial, for their excellent work, and all of the clinicians, not mentioned in the author list, who enrolled patients. We also thank the hematopathologists of the LYSA Pathology Commission for their pathology review (Dr. Danielle Canioni, Dr. Barbara Burroni, Prof. Alexandra Traverse-Glehen, Prof. Antoine Martin) and staff of the LYSA-Pathology core facility for providing their expert assistance for immunohisto-chemistry. We thank Estelle Gimenez for excellent technical coordination of the MRD work. We also thank our partners Mundipharma, Jannsen-Cilag, and Roche for funding. MBC acknowledges additional institutional support from the Université Grenoble-Alpes, Université Bourgogne-Franche Comté, INSERM and CNRS. Research funding via the French National Cancer Institute and the ITMO Cancer ‘Epigenetics and Cancer programme’ is also acknowledged. Finally, we thank Professor André Goy, chairman and executive director of the John Theurer Cancer Center, Hackensack for his critical review of the manuscript.</p>
</ack>
